Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Baxter
Fuji
Deloitte
Cerilliant
Dow
Cantor Fitzgerald
Harvard Business School
Merck

Generated: December 12, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DEUTETRABENAZINE

« Back to Dashboard

Clinical Trials for Deutetrabenazine

Trial ID Title Status Sponsor Phase Summary
NCT01795859 First Time Use of SD-809 in Huntington Disease Completed Teva Pharmaceutical Industries Phase 3 The purpose of this study is to determine whether SD-809 ER tablets are effective in the treatment of chorea associated with Huntington's Disease.
NCT01897896 Alternatives for Reducing Chorea in HD Active, not recruiting Auspex Pharmaceuticals, Inc. Phase 3 The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of SD-809 ER in subjects switching from tetrabenazine to SD-809 ER. In addition, the safety and tolerability of long term treatment with SD-809 ER will be assessed in "Switch" subjects as well as "Rollover" subjects completing a randomized, double blind, placebo controlled study of SD-809 ER,
NCT02195700 Aim to Reduce Movements in Tardive Dyskinesia Completed Auspex Pharmaceuticals, Inc. Phase 2/Phase 3 The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
NCT02198794 Reducing Involuntary Movements in Tardive Dyskinesia Active, not recruiting Auspex Pharmaceuticals, Inc. Phase 3 The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of SD-809 in reducing the severity of abnormal involuntary movements of moderate to severe tardive dyskinesia.
NCT02291861 Addressing Involuntary Movements in Tardive Dyskinesia Completed Auspex Pharmaceuticals, Inc. Phase 3 The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
NCT02674321 A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS) Completed Auspex Pharmaceuticals, Inc. Phase 1 The purpose of this study is to evaluate safety, tolerability and preliminary efficacy of SD-809 in the treatment of motor and phonic tics of Tourette Syndrome and to evaluate the pharmacokinetic of SD-809 and its metabolites.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Deutetrabenazine

Condition Name

Condition Name for Deutetrabenazine
Intervention Trials
Tourette Syndrome 4
Tardive Dyskinesia 3
Chorea Associated With Huntington Disease 1
Chorea 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Deutetrabenazine
Intervention Trials
Tourette Syndrome 4
Syndrome 4
Dyskinesias 3
Movement Disorders 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Deutetrabenazine

Trials by Country

Trials by Country for Deutetrabenazine
Location Trials
United States 115
Canada 3
Poland 3
Hungary 3
Czech Republic 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Deutetrabenazine
Location Trials
Texas 8
Alabama 6
New York 6
Florida 6
Maryland 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Deutetrabenazine

Clinical Trial Phase

Clinical Trial Phase for Deutetrabenazine
Clinical Trial Phase Trials
Phase 3 6
Phase 2/Phase 3 2
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Deutetrabenazine
Clinical Trial Phase Trials
Completed 4
Recruiting 3
Active, not recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Deutetrabenazine

Sponsor Name

Sponsor Name for Deutetrabenazine
Sponsor Trials
Auspex Pharmaceuticals, Inc. 5
Nuvelution TS Pharma, Inc. 3
Teva Branded Pharmaceutical Products, R&D Inc. 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Deutetrabenazine
Sponsor Trials
Industry 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
QuintilesIMS
Johnson and Johnson
Merck
McKesson
Julphar
Chubb
Fuji
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.